local_hospital

Sydvestjysk Sygehus

Address
lock Available on a paid plan

Cardiovascular Medicine and Metabolic Health

At Sydvestjysk Sygehus in Esbjerg, a large share of the research focuses on cardiovascular diseases and related nutritional and metabolic disorders. Studies are examining conditions such as atherosclerotic cardiovascular disease, acute myocardial infarction, atrial fibrillation, heart failure, and obesity, with the goal of improving prevention and reducing major cardiovascular events.

  • Testing new approaches to lower cardiovascular risk and prevent heart attacks, stroke, and related complications
  • Evaluating treatments for atrial fibrillation and safer ways to prevent stroke or systemic embolism
  • Studying therapies for heart failure, hypertriglyceridemia, and elevated lipoprotein(a)

These trials combine treatment evaluation with prevention-focused research, reflecting a strong clinical interest in long-term heart and metabolic health.

Kidney Disease and Diabetes-Related Research

The site also has active studies in renal medicine, especially chronic kidney disease, end-stage renal disease, and kidney complications linked to type 1 diabetes. This work aims to better understand disease progression and assess whether new treatments can protect kidney function and reduce cardiovascular risk.

  • Investigating therapies for chronic kidney disease and diabetic kidney complications
  • Exploring ways to slow kidney damage and preserve remaining kidney function
  • Assessing whether treatment can also lower broader risks such as heart failure and cardiovascular death

These studies support a more integrated approach to kidney and heart care, which is especially important for patients with long-term metabolic disease.

Respiratory, ENT, and Perioperative Care

Clinical research at Sydvestjysk Sygehus includes respiratory tract diseases, otorhinolaryngologic conditions, and supportive care around surgery. Trials are focused on chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyposis, and pain management in patients with obstructive sleep apnoea.

  • Comparing treatment options for COPD to improve symptom control and reduce exacerbations
  • Studying biologic therapies for chronic rhinosinusitis with nasal polyposis to improve daily symptoms and related health problems
  • Evaluating perioperative pain treatment to make surgery safer and more comfortable for patients with obesity and sleep-related breathing problems

This area of research combines symptom relief, treatment effectiveness, and safer care for patients with complex respiratory and surgical needs.

Neurology, Inflammation, and Immune-Mediated Disease

The research portfolio also includes studies in nervous system diseases and chronic inflammatory conditions. Current work addresses multiple sclerosis and polymyalgia rheumatica, aiming to improve long-term disease control and reduce relapse or symptom burden.

  • Assessing new treatments for multiple sclerosis with a focus on safety and sustained disease control
  • Testing whether therapy can help patients with polymyalgia rheumatica maintain remission after relapse
  • Supporting research on immune-related inflammation that affects mobility, pain, and quality of life

These studies reflect a broader interest in immune-driven disease and in finding better ways to manage chronic symptoms over time.

Hematology and Oncology

The department contributes to trials in hemic and lymphatic diseases and neoplasms, including diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The research is centered on comparing treatment strategies and improving outcomes for patients with blood cancers.

  • Evaluating new treatment combinations for lymphoma and leukemia
  • Comparing standard and alternative approaches to improve disease control
  • Studying options that may offer better effectiveness or tolerability for patients with hematologic cancer

These trials add an important oncology dimension to the site’s research activity, with a clear focus on better disease management and patient benefit.

Critical Care, Emergency Medicine, and Diagnostic Innovation

Another part of the clinical trial activity at the site involves urgent and high-acuity care, including hypotension, shock, and in-hospital cardiac arrest. Research in this area is aimed at improving immediate treatment decisions and outcomes in emergency settings.

  • Testing whether early treatment can improve control of shock in the emergency department
  • Evaluating therapies used during cardiac arrest to support return of circulation
  • Exploring better ways to manage unstable patients when rapid clinical decisions are needed

These studies show a practical focus on life-saving care, where even small improvements in response time and treatment choice can matter greatly.

Site Overview

assignment
97
connected trials
corporate_fare
36
sponsors
science
115
IMPs

Activity Indicator

Last 6 months

7
Trials started
-12% vs previous period.
8
Trials started 6–12 months ago
97
Total trials linked
Highly Active
trending_downDeclining-12%
2
1
1
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 21 therapeutic areas and 15 of 115 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 107 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
46
Sponsors (total)
36
Active sponsors
24

Sponsor Network

Top 24 by active trials.

lock +23 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +15 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 111 other sites in Denmark

description
Trial volume
97
Outperforms 93% of sites
public
Therapeutic diversity
22areas
Outperforms 92% of sites
groups
Sponsor diversity
36sponsors
Outperforms 90% of sites

Therapeutic Area Benchmark — Denmark

Select a therapeutic area to compare against other sites in Denmark.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Denmark

Market Share

Country: Denmark

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Sydvestjysk Sygehus

lock Showing 1 of 97 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 115 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Dapagliflozin5Unknown2022-10-072025-05-06

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.